ArticleAbdominal radiology (New York)2026
The additive value of morphologic grouping in assessing treatment response to ablative radiation therapy in liver metastases.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesTo assess the utility of Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and a modified version of previously proposed morphologic grouping in assessing treatment response to ablative radiotherapy in liver metastases.
methodsThis retrospective, single-institution study included consecutive patients with liver metastases who were treated with ablative radiotherapy and who underwent at least two follow-up abdominal contrast-enhanced CT scans from January 2017-November 2021. Two abdominal radiologists independently assessed baseline and follow-up scans based on RECIST 1.1 and a modified version of morphologic grouping originally proposed by the University of Texas MD Anderson Cancer Center. The association between each response assessment method with durable local control (i.e., decreased treated tumor size after radiation and stability over > 1 year on follow-up imaging with no progression of disease) and overall survival was assessed using multivariable generalized estimating equations and the univariable Cox proportional hazards model, respectively.
resultsOf 33 patients (17 men and 16 women; mean age at baseline, 63 years (range, 28-84); median follow-up, 368 days), 19/33 (58%) had durable local control. Modified morphologic grouping at the second, third, and fourth follow-up timepoints was associated with durable local control (P = 0.009, < 0.001, < 0.001, for Reader 1, and 0.003, < 0.001, < 0.001 for Reader 2). RECIST 1.1 at the third and fourth follow-up timepoints was associated with durable local control (P = 0.007 and 0.004 for Reader 1, and 0.008 and 0.01 for Reader 2). Neither was associated with overall survival (P = 0.15-0.24).
conclusionModified morphologic grouping-based response assessment of liver metastases treated with ablative radiotherapy may enable early detection of durable local control when compared to RECIST 1.1, especially at early follow-up timepoints.
Indexed as
Identifiers
40974478What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.